IdentificationGeneric Name(1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINEDrugBank Accession NumberDB07204BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE (DB07204)× CloseWeightAverage: 395.4564 Monoisotopic: 395.174610319 Chemical FormulaC24H21N5OSynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUcAMP-dependent protein kinase inhibitor alphaNot AvailableHumansUcAMP-dependent protein kinase catalytic subunit alphaNot AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as bipyridines and oligopyridines. These are organic compounds containing two pyridine rings linked to each other.KingdomOrganic compoundsSuper ClassOrganoheterocyclic compoundsClassPyridines and derivativesSub ClassBipyridines and oligopyridinesDirect ParentBipyridines and oligopyridinesAlternative ParentsNaphthyridines / 3-alkylindoles / Aralkylamines / Alkyl aryl ethers / Substituted pyrroles / Benzenoids / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Monoalkylamines / Hydrocarbon derivatives


 show 1 moreSubstituents3-alkylindole / Alkyl aryl ether / Amine / Aralkylamine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Bipyridine / Diazanaphthalene / Ether / Heteroaromatic compound / Hydrocarbon derivative / Indole / Indole or derivatives / Naphthyridine / Organic nitrogen compound / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Primary aliphatic amine / Primary amine / Pyrrole / Substituted pyrrole


 show 14 moreMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyDQIXTEDFNFZMCM-SFHVURJKSA-NInChIInChI=1S/C24H21N5O/c25-18(11-17-12-28-22-4-2-1-3-19(17)22)15-30-24-14-27-13-23-20(24)5-6-21(29-23)16-7-9-26-10-8-16/h1-10,12-14,18,28H,11,15,25H2/t18-/m0/s1IUPAC Name(2S)-1-(1H-indol-3-yl)-3-{[2-(pyridin-4-yl)-1,7-naphthyridin-5-yl]oxy}propan-2-amineSMILES[H][C@@](N)(COC1=C2C=CC(=NC2=CN=C1)C1=CC=NC=C1)CC1=CNC2=C1C=CC=C2ReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound6914614PubChem Substance99443675ChemSpider5290494BindingDB15066ChEMBLCHEMBL207496ZINCZINC000014957568PDBe Ligand6EAPDB Entries2f7zClinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.00297 mg/mLALOGPSlogP3.08ALOGPSlogP2.95ChemaxonlogS-5.1ALOGPSpKa (Strongest Acidic)17.11ChemaxonpKa (Strongest Basic)9.24ChemaxonPhysiological Charge1ChemaxonHydrogen Acceptor Count5ChemaxonHydrogen Donor Count2ChemaxonPolar Surface Area89.71 Å2ChemaxonRotatable Bond Count6ChemaxonRefractivity114.97 m3·mol-1ChemaxonPolarizability43.63 Å3ChemaxonNumber of Rings5ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleYesChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+1.0Blood Brain Barrier+0.9743Caco-2 permeable-0.7056P-glycoprotein substrateSubstrate0.5595P-glycoprotein inhibitor INon-inhibitor0.9181P-glycoprotein inhibitor IINon-inhibitor0.6456Renal organic cation transporterNon-inhibitor0.5527CYP450 2C9 substrateNon-substrate0.8828CYP450 2D6 substrateNon-substrate0.6271CYP450 3A4 substrateNon-substrate0.6234CYP450 1A2 substrateInhibitor0.8651CYP450 2C9 inhibitorNon-inhibitor0.7644CYP450 2D6 inhibitorInhibitor0.8832CYP450 2C19 inhibitorInhibitor0.6151CYP450 3A4 inhibitorInhibitor0.7428CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8851Ames testNon AMES toxic0.6125CarcinogenicityNon-carcinogens0.9418BiodegradationNot ready biodegradable1.0Rat acute toxicity2.3951 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.932hERG inhibition (predictor II)Inhibitor0.539  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn more


 Details1. cAMP-dependent protein kinase inhibitor alphaKindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionProtein kinase a catalytic subunit bindingSpecific FunctionExtremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulato...Gene NamePKIAUniprot IDP61925Uniprot NamecAMP-dependent protein kinase inhibitor alphaMolecular Weight7988.435 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] 


 Details2. cAMP-dependent protein kinase catalytic subunit alphaKindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionUbiquitin protein ligase bindingSpecific FunctionPhosphorylates a large number of substrates in the cytoplasm and the nucleus. Regulates the abundance of compartmentalized pools of its regulatory subunits through phosphorylation of PJA2 which bin...Gene NamePRKACAUniprot IDP17612Uniprot NamecAMP-dependent protein kinase catalytic subunit alphaMolecular Weight40589.38 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:19 / Updated at June 12, 2020 16:52 